Locanabio Announces Presentation of Preclinical Data Demonstrating an Improved Vectorized snRNA Platform with Applications in Exon Skipping for the Potential Treatment of Duchenne Muscular Dystrophy (DMD) at the 28th Annual Congress of the World Muscle So

<p>Locanabio expects to submit IND application in mid-2024 for first program, LBIO-115, designed to promote skipping of exon 51 in the dystrophin RNA transcript SAN DIEGO, Oct. 06, 2023 (GLOBE NEWSWIRE) — Locanabio, Inc., a genetic medicines company developing RNA-targeted therapeutics for patients with rare genetic neuromuscular and neurodegenerative diseases, today announced the presentation of […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/locanabio-announces-presentation-of-preclinical-data-demonstrating-an-improved-vectorized-snrna-platform-with-applications-in-exon-skipping-for-the-potential-treatment-of-duchenne-muscular-dystrophy/">Locanabio Announces Presentation of Preclinical Data Demonstrating an Improved Vectorized snRNA Platform with Applications in Exon Skipping for the Potential Treatment of Duchenne Muscular Dystrophy (DMD) at the 28th Annual Congress of the World Muscle Society (WMS2023)</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>